- Conditions
- Childhood Cancer, Multiple Diseases
- Interventions
- Immunization Schedule patients <7 years., Immunization Schedule patients > or = to 7 years and <11 years of age, Immunization Schedule patients > or = to 11 years of age
- Biological
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 2 Years to 18 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2025
- U.S. locations
- 1
- States / cities
- New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–72
of 121
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Infections, Meningococcal
- Interventions
- Meningococcal vaccine GSK134612
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 2 Years to 6 Years
- Enrollment
- 387 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2014
- U.S. locations
- 14
- States / cities
- Benton, Arkansas • Little Rock, Arkansas • Antioch, California + 10 more
- Conditions
- Meningococcal Infections, Meningitis
- Interventions
- Menactra®, Menomune®
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 14 Years to 27 Years
- Enrollment
- 763 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2009
- U.S. locations
- 20
- States / cities
- Little Rock, Arkansas • Fountain Valley, California • Marietta, Georgia + 15 more
- Conditions
- Meningococcal Infections
- Interventions
- Trumenba Vaccine (Wyeth/Pfizer Pharmaceuticals)
- Biological
- Lead sponsor
- UCSF Benioff Children's Hospital Oakland
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 2
- States / cities
- Oakland, California • Worcester, Massachusetts
- Conditions
- Meningitis, Meningococcal Meningitis, Meningococcal Infections
- Interventions
- Menomune®: A, C, Y, W 135 Meningococcal Polysaccharide, Menactra®: Meningococcal (A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate
- Biological
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 56 Years and older
- Enrollment
- 139 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2012
- U.S. locations
- 6
- States / cities
- Scottsdale, Arizona • Bardstown, Kentucky • Albuquerque, New Mexico + 3 more
- Conditions
- Alopecia Areata
- Interventions
- PF-06651600, Tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccine, Meningococcal (groups A, C, W-135 and Y [ACWY]) oligosaccharide diphtheria CRM197 conjugate vaccine
- Drug · Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 1,057 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 47
- States / cities
- Birmingham, Alabama • Beverly Hills, California • Irvine, California + 28 more
- Conditions
- Meningococcal Meningitis
- Interventions
- MenACWY-CRM conjugate vaccine, Licensed comparator
- Biological
- Lead sponsor
- Novartis Vaccines
- Industry
- Eligibility
- 11 Years to 18 Years
- Enrollment
- 389 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2012
- U.S. locations
- 32
- States / cities
- Birmingham, Alabama • Fremont, California • Fresno, California + 21 more
- Conditions
- Meningitis, Meningococcal
- Interventions
- Meningococcal ACWY Conjugate Vaccine, DTaP-IPV-HBV, Hib, Rotavirus, Pneumococcal 7-valent Conjugate Vaccine, HAV, MMR-V, DTaP
- Biological
- Lead sponsor
- Novartis Vaccines
- Industry
- Eligibility
- 2 Months to 2 Months
- Enrollment
- 4,545 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2009
- U.S. locations
- 53
- States / cities
- Bessemer, Alabama • Birmingham, Alabama • Downey, California + 43 more
- Conditions
- Meningitis, Meningococcal Infection
- Interventions
- Quadrivalent Meningococcal Polysaccharide (A, C, Y, and W-135) Tetanus Protein Conjugate, Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus B Conjugate (Tetanus Toxoid Conjugate) Vaccine Combined (DTaP-IPV/Hib combined), M-M-RII-Measles, Mumps, and Rubella Virus Vaccine Live, Varicella Virus Vaccine Live, Pneumococcal 7-valent Conjugate Vaccine (Diphtheria CRM197 Protein), Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM197 Protein), Rotavirus Vaccine, Hepatitis B Vaccine
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 42 Days to 365 Days
- Enrollment
- 580 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2012
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Tuscaloosa, Alabama • Jonesboro, Arkansas + 20 more
- Conditions
- Meningococcal Disease, Infections, Meningococcal
- Interventions
- Meningococcal quadrivalent CRM-197 conjugate vaccine
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 2 Months to 23 Months
- Enrollment
- 144 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Pasadena, California
- Conditions
- Meningococcal Infections, Meningococcal Meningitis
- Interventions
- MenACWY CRM, Meningococcal ACWY Conjugate vaccine
- Biological
- Lead sponsor
- Novartis Vaccines
- Industry
- Eligibility
- 11 Years to 55 Years
- Enrollment
- 3,539 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 40
- States / cities
- Birmingham, Alabama • Tuscaloosa, Alabama • Fremont, California + 37 more
- Conditions
- Meningitis, Meningococcal Infection
- Interventions
- Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate: Menactra®
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 15 Years to 55 Years
- Enrollment
- 834 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 15
- States / cities
- Little Rock, Arkansas • San Diego, California • Bardstown, Kentucky + 12 more
- Conditions
- Infections, Meningococcal
- Interventions
- rMenB+OMV NZ vaccine, Meningococcal Groups A, C, W and Y Conjugate Vaccine (MenACWY), Placebo, MenABCWY-1, MenABCWY-2, MenABCWY-3
- Combination Product · Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 10 Years to 25 Years
- Enrollment
- 3,657 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 64
- States / cities
- Chandler, Arizona • Glendale, Arizona • Jonesboro, Arkansas + 51 more
- Conditions
- Meningococcal Disease
- Interventions
- MenABCWY, Placebo, MenACWY
- Biological · Other
- Lead sponsor
- Novartis Vaccines
- Industry
- Eligibility
- 10 Years to 18 Years
- Enrollment
- 305 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 8
- States / cities
- Huntsville, Alabama • Jonesboro, Arkansas • Melbourne, Florida + 5 more
- Conditions
- Meningitis, Meningococcal Infection
- Interventions
- Meningococcal Polysaccharide Diphtheria Protein Conjugate (Menactra®), A/C/Y/W-135, Meningococcal Polysaccharide Vaccine (Menomune®)
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 9 Months to 5 Years
- Enrollment
- 378 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004 – 2007
- U.S. locations
- 14
- States / cities
- Little Rock, Arkansas • Norwich, Connecticut • Atlanta, Georgia + 11 more
- Conditions
- Infections, Meningococcal
- Interventions
- Bexsero (GSK Biologicals' Meningococcal group-B vaccine/ rMenB+OMV NZ), Prevnar13, Pediarix, Hiberix, Rotarix, M-M-R II, Varivax, Placebo (saline water), Prevnar 20
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 6 Weeks to 12 Weeks
- Enrollment
- 1,196 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2024
- U.S. locations
- 56
- States / cities
- Birmingham, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 47 more
- Conditions
- Meningitis, Meningococcemia, Neisseria Meningitidis
- Interventions
- A/C/Y/W-135, Meningococcal Polysaccharide Vaccine (Menomune®)
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 3 Years to 5 Years
- Enrollment
- 173 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003 – 2004
- U.S. locations
- 8
- States / cities
- Jonesboro, Arkansas • Little Rock, Arkansas • Woburn, Massachusetts + 5 more
- Conditions
- Infections, Meningococcal
- Interventions
- Meningococcal vaccine 134612, Menactra®
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 10 Years to 25 Years
- Enrollment
- 873 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2008
- U.S. locations
- 10
- States / cities
- Daly City, California • Fairfield, California • Redwood City, California + 6 more
- Conditions
- Gonorrhea Male
- Interventions
- Cefixime, Ceftriaxone, Ciprofloxacin, Neisseria gonorrhoeae strain FA1090, Meningococcal Group B Vaccine, Influenza Vaccine, Tetanus-diptheria Vaccine
- Drug · Biological
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years to 35 Years · Male only
- Enrollment
- 65 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Infections, Meningococcal
- Interventions
- Meningococcal Group B Vaccine (GSK3536829A) (rMenB+OMV NZ), Meningococcal MenACWY Conjugate Vaccine (GSK3536820A) (MenA lyo + MenCWY liquid), Placebo
- Combination Product · Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 16 Years to 18 Years
- Enrollment
- 945 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 49
- States / cities
- Phoenix, Arizona • Bell Gardens, California • Los Angeles, California + 35 more
- Conditions
- Meningococcal Immunisation, Healthy Volunteers
- Interventions
- Multicomponent Meningococcal B Vaccine, Meningococcal Group B Vaccine MenB, Meningococcal Group B Vaccine (recombinant deoxyribonucleic acid [rDNA], component, adsorbed), Placebo, Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine MenACYW conjugate vaccine
- Drug
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 42 Days to 50 Years
- Enrollment
- 576 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 8
- States / cities
- Guntersville, Alabama • San Diego, California • Tampa, Florida + 5 more
- Conditions
- Prevention of Meningococcal Disease
- Interventions
- MenACWY-CRM Vaccine, MenACWY-PS Vaccine
- Biological
- Lead sponsor
- Novartis Vaccines
- Industry
- Eligibility
- 12 Months to 10 Years
- Enrollment
- 910 participants
- Timeline
- 2005 – 2006
- U.S. locations
- 1
- States / cities
- Oakland, California
- Conditions
- Infections, Meningococcal
- Interventions
- GSK Biologicals' Meningococcal vaccine GSK134612 (Nimenrix), GSK Biologicals' Hib-meningococcal vaccine GSK 792014 (Menhibrix), Infanrix®, ActHIB®, Pediarix®
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 6 Weeks to 12 Weeks
- Enrollment
- 1,558 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2009
- U.S. locations
- 56
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Benton, Arkansas + 50 more
- Conditions
- Meningococcal Disease, Pregnancy, Infections, Meningococcal
- Interventions
- Meningococcal quadrivalent CRM-197 conjugate vaccine
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- Female only
- Enrollment
- 93 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 2
- States / cities
- Wilmington, North Carolina